stockrow
Friday 6 November 2026
Export TRAX’s income statement to Excel — free account
First Tracks Biotherapeutics, Inc.
TRAX Healthcare Biotechnology
- EPS
- +40.5%
- Free cash flow
- +55.9%
Quarter to September 2026, against a year earlier
47.78
2.35
+5.17%
Follow TRAX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
9.16 | 14.28 | 8.74 | 10.20 |
+3 more quarters Free account |
Net Debt/EBITDA |
4.89 | 4.86 | 5.44 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | — | — | |
Operating CF/Net income |
0.54 | 0.96 | 0.65 | — | |
Capex/Depreciation |
0.00 | (0.07) | (0.15) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(0.48) | (0.91) | 0.00 | — | |
Cash per Share |
4.35 | 4.80 | 0.00 | 0.00 | |
Shareholders Equity per Share |
4.22 | 4.82 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | — | |
Book value per Share |
4.22 | 4.82 | 0.00 | 0.00 | |
Free Cash Flow |
(17.05) | (31.94) | (32.58) | — | |
Working Capital |
147.63 | 165.30 | 256.29 | 285.38 | |
Capital Expenditures |
0.00 | (0.02) | (0.02) | — | |
Net Current Asset Value |
146.28 | 163.40 | 256.29 | 273.35 | |
| Other line items | |||||
Quick Ratio |
8.60 | 13.50 | 8.65 | 10.05 | |
Revenue per Share |
0.00 | 0.00 | — | — | |
Operating CF per Share |
(0.48) | (0.91) | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Average Assets |
— | 91.57 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 5 Nov 2026